Evidence map›Paper›PMID 38746488›Full record

ArticleCureus2024

Abiraterone-Induced Secondary Hypertension: Two Wrongs Don't Make a Right.

Achilleas Betsikos, Eleni Paschou, Virginia Geladari, Stauroula Magaliou, Nikolaos Sabanis

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Achilleas BetsikosFirst Department of Internal Medicine, General Hospital of Trikala, Trikala, GRC.
Eleni PaschouGeneral Practice and Family Medicine, 10th Local Medical Unit of Giannouli, Larisa, GRC.
Virginia GeladariFirst Department of Internal Medicine, General Hospital of Trikala, Trikala, GRC.
Stauroula MagaliouNephrology Department, General Hospital of Trikala, Trikala, GRC.
Nikolaos SabanisNephrology Department, General Hospital of Trikala, Trikala, GRC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abiraterone, an inhibitor of both 17α-hydroxylase and 17,20-lyase, is considered a novel, state-of-the-art, life-prolonging therapy in the urologists' arsenal when treating prostate cancer. Despite its efficacy, it is linked with an increased risk of cardiovascular adverse effects. Herein, we report a case in which the administration of abiraterone resulted in a full-blown syndrome of apparent mineralocorticoid excess despite the concomitant administration of prednisolone; that is, secondary hypertension, hypokalemia, metabolic alkalosis, as well as elevated levels of adrenocorticotropic hormone (ACTH).

Indexed as

abirateronehypokalemiamineralocorticoid excess syndromeprostate cancer (pca)secondary hypertension

Identifiers

PMID38746488
PMCPMC11093521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.